Latest Views & News

How much will GlaxoSmithKline shareholders love Haleon?

By Chris Bailey | Monday 28 February 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

If you are a GlaxoSmithKline (GSK) investor, you may have noted last week that the FTSE-100 company observed the new name for its consumer health business ‘Haleon’ is from “Hale” (meaning in good health) and “Leon” (which it claimed was associated with strength) and declared it was to be pronounced “Hay-Lee-On”. Enjoy mispronouncing that! Of course the urban dictionary’s definition is a little bit alternative to this… So should GlaxoSmithKline’s shareholders be excited or concerned about July’s upcoming business split of the consumer health and core pharmaceutical business?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was